Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Conditions

• Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
• Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
• Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
• Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
• Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
• Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
• Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
• Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
• Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

• PROCEDURE: Biospecimen Collection
• PROCEDURE: Computed Tomography
• PROCEDURE: Positron Emission Tomography
• DRUG: Tegavivint
• PROCEDURE: Bone Marrow Biopsy
• PROCEDURE: Bone Marrow Aspiration

Sponsor

Lapo Alinari